Context Therapeutics Announces Poster Presentation at the American Association for Cancer Research (AACR) Annual Meeting 2025PHILADELPHIA, March 26, 2025 (GLOBE NEWSWIRE) -- Context Therapeutics Inc. (“Context” or the “Company”) (Nasdaq: CNTX), a clinical-stage biopharmaceutical company advancing T cell engaging (“TCE”) bispecific antibodies for solid tumors, today announced a poster regarding the Company’s clinical asset, CT-95, a mesothelin (“MSLN”) x CD3 TCE will be presented at the American Association for Cancer Research (AACR) Annual Meeting 2025, taking place April 25-30, 2025 in Chicago, IL.
Context Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)PHILADELPHIA, Feb. 24, 2025 (GLOBE NEWSWIRE) -- Context Therapeutics Inc. (“Context” or the “Company”) (Nasdaq: CNTX), a biopharmaceutical company advancing medicines for solid tumors, today announced that Context has granted non-qualified stock option awards to purchase an aggregate of 46,000 shares of its common stock to two new employees as an inducement material for accepting employment with Context.
Context Therapeutics to Participate in Upcoming Investor ConferencesPHILADELPHIA, Feb. 19, 2025 (GLOBE NEWSWIRE) -- Context Therapeutics Inc. (“Context” or “Company”) (Nasdaq: CNTX), a biopharmaceutical company advancing T cell engagers for solid tumors, today announced that the Company will participate in the following investor conferences:
Context Therapeutics Reports Third Quarter 2024 Operating and Financial ResultsExpands pipeline of T cell engaging bispecific antibodies through acquisitions of CT-95, a Mesothelin x CD3 bispecific antibody, and CT-202, a Nectin-4 x CD3 bispecific antibody
Context Therapeutics to Participate in Upcoming Investor Conferences in NovemberPHILADELPHIA, Oct. 23, 2024 (GLOBE NEWSWIRE) -- Context Therapeutics Inc. (“Context” or “Company”) (Nasdaq: CNTX), a biopharmaceutical company advancing T cell engagers for solid tumors, today announced that the Company will participate in the following investor conferences in November:
Context Therapeutics Announces Poster Presentation at the Society for Immunotherapy of Cancer’s (SITC) 39th Annual MeetingPHILADELPHIA, Oct. 16, 2024 (GLOBE NEWSWIRE) -- Context Therapeutics Inc. (“Context” or “Company”) (Nasdaq: CNTX), a biopharmaceutical company advancing T cell engagers for solid tumors, today announced a poster regarding the Company’s clinical asset, CTIM-76, a Claudin 6 x CD3 bispecific antibody will be presented at the Society for Immunotherapy of Cancer’s (SITC) 39th Annual Meeting, being held November 8–10, 2024 at the George R. Brown Convention Center in Houston, TX.
Context Therapeutics Appoints Dr. Karen Smith and Dr. Luke Walker to Board of DirectorsThe appointments of Dr. Karen Smith and Dr. Luke Walker to the Board bring extensive operational and clinical development experience to support corporate and pipeline strategy
Context Therapeutics Appoints Chief Medical Officer and Vice President of Clinical OperationsCompany announces appointments of Dr. Claudio Dansky Ullmann as CMO and Ms. Karen Andreas as VP, Clinical Operations
Context Therapeutics Acquires Phase 1-ready T cell Engager CT-95CT-95 is a potentially first-in-class mesothelin x CD3 bispecific antibody
Context Therapeutics Reports First Quarter 2024 Operating and Financial ResultsAnnounced FDA clearance of IND application for a Phase 1 clinical trial of CTIM-76
Context Therapeutics Announces $100 Million Private PlacementFinancing includes new and existing leading healthcare investors
10 Biotech Stocks Below Cash Value with Key Catalysts on the Horizon: An AnalysisNEW YORK, NY / ACCESSWIRE / October 24, 2023 / The biotech sector, known for its exponential growth potential, is currently facing highly challenging market conditions. Influences like rising inflation, geopolitical tensions, and looming economic recessions have led to a sharp decline in the sector. Consequently, many small and micro-cap biotech companies are trading at all-time lows, with several down by over 80-90% in recent years. This downturn has led to many biotech firms trading below their cash holdings.
Context Therapeutics Announces Acceptance of Abstract to be Presented at the Society for Immunotherapy of Cancer’s (SITC) 38th Annual MeetingPHILADELPHIA, Sept. 27, 2023 (GLOBE NEWSWIRE) -- Context Therapeutics Inc. (“Context” or the “Company”) (Nasdaq: CNTX), a biopharmaceutical company advancing medicines for solid tumors, today announced a poster regarding the Company’s preclinical asset, CTIM-76, a Claudin 6 x CD3 bispecific antibody will be presented at the Society for Immunotherapy of Cancer’s (SITC) 38th Annual Meeting taking place November 3-5, 2023, at the San Diego Convention Center in San Diego, CA.
Context Therapeutics CEO Marty Lehr notes progress towards the clinic with CTIM-76 in 2Q updateContext Therapeutics (
NASDAQ:CNTX) CEO Marty Lehr takes Proactive's Stephen Gunnion through progress with the company's lead program, CTIM-76.
Context Therapeutics Reports Second Quarter 2023 Operating and Financial ResultsCompany expects its cash and cash equivalents will continue to fund operations into late 2024
